Cogent Hits ‘Unprecedented’ Efficacy in Rare Stomach Cancer, Clearing Path to FDA

Cogent Biosciences expects to file a new drug application for bezuclastinib in gastrointestinal stromal tumors early next year after what Leerink said was “the first positive trial in this disease in over a decade.”